Quest Diagnostics boosts share repurchase by $1B; Magellan Dx wins 510(k) for lead level test;

> Quest Diagnostics ($DGX) says its board increased a share repurchase plan by $1 billion. Story

> Ireland's Trinity Biotech is paying nearly $34 million for Immco, a suburban Buffalo, NY, maker of autoimmune disease diagnostic kits. Story

> Magellan Diagnostics in Billerica, MA, won the FDA's 510 (k) clearance to market its new test designed to measure lead levels in the blood. Item

> MBio Diagnostics in Boulder, CO, has expanded its board of directors, adding entrepreneur Robert Silverman to the team. Item

> Startup Global Cancer Diagnostics in Tempe, AZ, is a finalist for a national crowdfunding contest for emerging small businesses. Item

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.